🔥COPILOT: Completion Of Pembrolizumab In advanced NSCLC
🎙️Dr. A Fantoni Clinical Lung Cancer
🎯Real world Outcomes after Two years of therapy ()
✅Observational study
✅Primary: PFS
✅AUstralian Registry and biObank of thoRacic cAncers (AURORA)
#LCSM OncoAlert
clinical-lung-cancer.com/article/S1525-…

🔥The IASLC Staging Project for Lung Cancer: Recommendation to Introduce Spread Through Air Spaces (STAS) as a Histologic Descriptor in the 9th Ed TNM
🎙️Dr. William D. Travis JTO & JTO CRR
🎯Analysis of 4061 Pathologic Stage I NSCLC
#LCSM OncoAlert
jto.org/article/S1556-…

🔥Guardrails for the use of generalist AI in cancer care
🎙️Dr. Stephen Gilbert Nature Reviews Cancer
✅The spectrum of technologies for clinical decision support, classified as device or non-device for regulatory purposes.
#LCSM OncoAlert
nature.com/articles/s4156…

Clinical cancer research and care are evolving at unprecedented speeds. Join us at ASCO Breakthrough to discover the latest cutting-edge advances spanning multiple disease sites that will keep you at the forefront of innovation that is shaping clinical cancer care.

⚡Our April issue is live! Featuring studies on #cancer #vaccines & #neoadjuvant therapy, clinical #AI , an #AlzheimersDisease blood test, telehealth #abortion , #ParkinsonsDisease , #T2D , and much more including news, reviews & opinion.
nature.com/nm/volumes/30/…

Dr. Xiuning Le MD PhD at #TexasLung24 gives a brilliant breakdown of frontline #EGFR combination strategies including adding amivantamab to TKI (MARIPOSA) and targeting VEGF (RAMOSE). TLC Conference

A timely discussion with Narjust Florez, MD, FASCO amazing host of @iaslc Lung Cancer Considered podcast about the ALINA trial given the recent U.S. FDA approval of adjuvant alectinib for resected ALK+ NSCLC! Thanks Narjust Florez, MD, FASCO ! #LCSM

In the wake of the U.S. FDA approval of alectinib for resected #NSCLC , host Narjust Florez, MD, FASCO & guest Ben Solomon discuss this development & take a deeper look at the ALINA trial, which included pts w/resected stage II/III NSCLC w/an ALK fusion: bit.ly/AlectinibFDA24 #LCSM

🔥Embracing cancer complexity
🎙️Charles Swanton Cell
🎯Tumor initiation & promotion, micro- & immune macro-environments, aging, metabolism & obesity, cachexia, circadian rhythms, nervous system, thrombosis, and the microbiome
#LCSM OncoAlert
cell.com/cell/fulltext/…

🔥Cancer biomarkers
🎙️Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ Cell
🎯Emerging trends and clinical implications for personalized treatment
✅Cancer detection, diagnosis, and subclassification
✅Inform treatment decision-making
✅Characterize immune response
#LCSM OncoAlert
cell.com/cell/fulltext/…

🔥How does a cancer vaccine work?
🎙️Liam Drew Cell
🎯After decades of slow progress, therapeutic vaccines that direct the immune system to attack tumors could soon become a fixture of cancer treatment.
#LCSM OncoAlert
nature.com/articles/d4158…

🔥Antiangiogenic–immune-checkpoint inhibitor combinations
🎙️Dr. Hung-Yang Kuo NatureRevClinOncol
🎯Lessons from phase III clinical trials
✅Balance between beneficial and detrimental effects of antiangiogenic–ICI combinations
#LCSM OncoAlert
nature.com/articles/s4157…

🔥Pembrolizumab + chemo for metastatic NSCLC with PD-L1 TPS < 1%
🎙️Dr. Shirish M. Gadgeel JTO & JTO CRR IASLC
🎯KEYNOTE series trials after 5 years of F/U
✅Pooled Analysis
✅Primary: OS
✅NCT02578680, NCT03950674, NCT02775435, NCT03875092
#LCSM OncoAlert
jto.org/article/S1556-…

Just Out
U.S. FDA 🇺🇸 approves alectinib for adjuvant treatment following tumor resection in patients with ALK positive non-small cell lung cancer #NSCLC 🫁 Based on Results from ALINA

fda.gov/drugs/resource…

Christian Rolfo gilberto lopes Narjust Florez, MD, FASCO Stephen V Liu, MD H. Jack West, MD

Just released! The 2023 #IASLC Annual Report is live. With 10,000+ members & new innovative initiatives, we're making strides in thoracic cancer research. Let's join together, grow together, & succeed together! Learn more: bit.ly/IASLCAnnualRep…

🔥🚨OncoAlert HOT OFF THE PRESS

BIG NEWS

U.S. FDA approves #Adjuvant #Alectinib following surgery in patients with stage IB-IIIA #ALK +Non-Small Cell #LungCancer based on results of #Alina trial:
⬆️ #DFS HR: 0.24 (compared with adjuvant chemotherapy).

👇🏼
fda.gov/drugs/resource…

🔥Targeting KRAS in cancer
🎙️Dr. Anupriya Singhal Nature Medicine
🎯Global review on treatment and resistant mechanisms
✅‘On’ and ‘off’ switch allele-specific inhibitors
✅‘Pan’ RAS inhibitors
✅Immunotherapy
#LCSM OncoAlert
nature.com/articles/s4159…

🔥The ADC landscape
🎙️Patrick Flynn Nature Reviews Drug Discovery
🎯Revenue from approved and phase III ADCs is forecasted to reach $26 billion in 2028
✅Reviewing pipeline across 5 aspects: target, payload MoA, antibody, linker & conjugation method
#LCSM OncoAlert
nature.com/articles/d4157…

Just out by our OncoAlert 🚨 #LungCancer Faculty Christian Rolfo 🇺🇸and team

Study suggests circulating tumor DNA (ctDNA)🧬 tumor fraction (TF) could enhance liquid biopsy accuracy in detecting true negative results

✅Aiding in decision-making for follow-up tissue testing in

Congratulations to all of these IASLC Academy participants - early-career physicians interested in academic careers in thoracic oncology, partnered with expert mentors through the year. Looking forward to seeing all that you do!